Clinical/Research Interests

Specialty:

Center/Program Affiliation:

Address:

Phone:

Education:

Internships:

Residency:

Fellowships:

Board Certifications:

Professional Memberships:

Select Recent Publications:

Schillaci O, DeNardo GL, DeNardo SJ, Goldstein DS, Kroger LA, O'Donnell RT, Lamborn KR. Effect of anti-lymphoma antibody, 131ILym-1 on peripheral blood lymphocytes in patients with non-Hodgkin's lymphoma. Cancer Biother Radiopharm, 22(4): 521-530.2007

Semrad TJ, O'Donnell RT, Wun T, Chew H, Harvey D, Zhou H, White RH. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg, 106(4): 601-608.2007.

Lehmann J, DeNardo GL, Yuan A, Shen S, ODonnell RT, Richman CR, DeNardo SJ. Comparison of normal tissue pharmacokinetics with 111In/90Y monoclonal antibody m170 for breast and prostate cancer. International Journal of Radiation Oncology. Biology and Physics, 66(4): 1192-1198.2006.

O'Donnell RT. Nuclear Localizing Sequences: An Innovative Way to Improve Targeted Radiotherapy. Journal of Nuclear Medicine. Invited Perspective, 47(5): 738-739.2006.

Chen AY, H Lee, J Hartman, C Greco, JK Ryu, RT O'Donnell, J Boggan. Secondary supratentorial primitive neuroectodermal tumor following irradiation in a patient with low-grade astrocytoma. American Journal of Neuroradiology 26(1):1-3.

Shen S, SJ DeNardo, CM Richman, A Yuan, C Hartman Siantar, RT O'Donnell, LA Kroger, GL DeNardo. Planning time for peripheral blood stem-cell infusions after high-dose targeted radionuclide therapy using dosimetry. Journal of Nuclear Medicine. 46(6):1034-1041.

DeNardo SJ, CM Richman, H Albrecht, PA Burke, A Natarajan, A Yuan, JP Gregg, RT O'Donnell, GL DeNardo. Enhancement of the therapeutic index: From non-myeloablative and myeloablative toward pre-targeted radioimmunotherapy for metastatic prostate cancer. Clinical Cancer Research (in press).

Richman CM, SJ DeNardo, RT O'Donnell. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporin to suppress HAMA. Clinical Cancer Research. 11(16):5920-5927.

Martel C, Y Li, L Beckett, H Chew, S Christensen, A Davies, KS Lam, DH Lau, FJ Meyers, RT O'Donnell, C Richman, S Scudder, M Tanaka, JM Tuscano, J Welborn, T Wun, DR Gandara, PN Lara. An evaluation of barriers to accrual in the era of legislation requiring insurance coverage of cancer clinical trial costs in California. The Cancer Journal 10(5):294-300.

DeNardo SJ, Y Zhengsheng, K Lam, A Song, PA Burke, GR Mirick, KR Lamborn, RT O'Donnell, GL DeNardo. Effect of molecular size of pegylated peptide on the pharmacokinetics and tumor targeting in lymphoma-bearing mice. Clinical Cancer Research 9:3854-3864s.